Impact of 3 different short-term chemotherapy regimens on lymphocyte-depletion and reconstitution in melanoma patients

Journal of Immunotherapy

Volumn 33, Issue 7, 2010, Pages 723-734

  Laurent, Julien ^a   Speiser, Daniel E ^a   Appay, Victor ^b   Touvrey, Cedric ^a   Vicari, Manuela ^a   Papaioannou, Anne ^a   Canellini, Giorgia ^c   Rimoldi, Donata ^a   Rufer, Nathalie ^a   Romero, Pedro ^a   Leyvraz, Serge ^a   Voelter, Verena ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b INSERM   (France)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

antigen specific CD8 T cells; chemotherapy; melanoma; vaccination

Indexed keywords

BUSULFAN; CANCER TESTIS ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; FREUND ADJUVANT; GLUTAMYLLEUCYLALANYLGLYCYLISOLEUCYLGLYCYLISOLEUCYLLEUCYLTHREONYLVALINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 15; INTERLEUKIN 7; MELAN A; MELANOMA ANTIGEN 10; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MESNA; NY ESO 1 ANTIGEN; SSX 2 PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VALACICLOVIR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER IMMUNIZATION; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTAPHERESIS; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; EFFECTOR CELL; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; FEMALE; HEMORRHAGIC CYSTITIS; HOMEOSTASIS; HUMAN; LOW DRUG DOSE; LYMPHOCYTAPHERESIS; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFER; MALE; MELANOMA; METASTASIS; NEUTROPHIL COUNT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT COURSE THERAPY; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION;

EID: 77955174496     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ea7e6e     Document Type: Article

References (39)

1. Krupica T, Fry TJ, Mackall CL. Autoimmunity during lymphopenia: a two-hit model. Clin Immunol. 2006;120: 121-128.
2. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmu-nity. J Clin Invest. 2002;110:185-192.
3. Ma J, Urba WJ, Si L, et al. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol. 2003;33: 2123-2132.
4. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphode-pleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23: 2346-2357.
5. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol. 2007;19:318-330.
6. Prlic M, Blazar BR, Khoruts A, et al. Homeostatic expansion occurs independently of costimulatory signals. J Immunol. 2001;167:5664-5668.
7. Tanchot C, Rosado MM, Agenes F, et al. Lymphocyte homeostasis. Semin Immunol. 1997;9:331-337.
8. Bolotin E, Annett G, Parkman R, et al. Serum levels of IL-7 in bone marrow transplant recipients: relationship to clinical characteristics and lymphocyte count. Bone Marrow Transpl. 1999;23:783-788.
9. Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood. 2001;97:2983-2990.
10. Appay V, Voelter V, Rufer N, et al. Combination of transient lymphodepletion with busulfan and fludarabine and peptide vaccination in a phase I clinical trial for patients with advanced melanoma. J Immunother. 2007;30:240-250.
11. Evans R, Kamdar SJ, Duffy TM, et al. The therapeutic efficacy of murine anti-tumor T cells: freshly isolated T cells are more therapeutic than T cells expanded in vitro. Anticancer Res. 1995;15:441-447.
12. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med. 1995;333:1038-1044.
13. Rooney CM, Roskrow MA, Smith CA, et al. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998;23:89-93.
14. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11:1230-1237.
15. Gattinoni L, Zhong XS, Palmer DC, et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009;15:808-813.
16. Haanen JB, Schumacher TN. Vaccine leads to memory loss. Nat Med. 2007;13:248-250.
17. Proietti E, Greco G, Garrone B, et al. Importance of cyclophosphamide- induced bystander effect on T cells for a successful tumor eradication in response to adoptive immu-notherapy in mice. J Clin Invest. 1998;101:429-441.
18. Ghiringhelli F, Larmonier N, Schmitt E, et al. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol. 2004;34:336-344.
19. Gunturu KS, Meehan KR, Mackenzie TA, et al. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol. 2010;28: 1196-1202.
20. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, et al. CD25+ CD4+ T cells regulate the expansion of peripheral CD4T cells through the production of IL-10. J Immunol. 2001;166:3008-3018.
21. Giraud S, Barrou B, Sebillaud S, et al. Transient depletion of dividing T lymphocytes in mice induces the emergence of regulatory T cells and dominant tolerance to islet allografts. Am J Transplant. 2008;8:942-953.
22. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005;11:1238-1243.
23. Ferrari S, Rovati B, Porta C, et al. Lack of dendritic cell mobilization into the peripheral blood of cancer patients following standard-or high-dose chemotherapy plus granulo-cyte-colony stimulating factor. Cancer Immunol Immunother. 2003;52:359-366.
24. Fry TJ, Mackall CL. The many faces of IL-7: from lymphopoiesis to peripheral T cell maintenance. J Immunol. 2005;174:6571-6576.
25. Schluns KS, Kieper WC, Jameson SC et al. Interleukin-7 mediates the homeostasis of naive and memory CD8T cells in vivo. Nat Immunol. 2000;1:426-432.
26. Puel A, Ziegler SF, Buckley RH et al. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat Genet. 1998;20:394-397.
27. Gattinoni L, Finkelstein SE, Klebanoff CA, et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med. 2005;202:907-912.
28. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233-5239.
29. Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789-3798.
30. Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84:2221-2228.
31. Powell DJ Jr, Dudley ME, Hogan KA, et al. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol. 2006;177:6527-6539.
32. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25:243-251.
33. Antonarakis ES, Carducci MA. Combining low-dose cyclo-phosphamide with GM-CSF-secreting prostate cancer immu-notherapy enhances antitumor immune effects. Expert Opin Investig Drugs. 2010;19:311-314.
34. Waller EK. The role of sargramostim (rhGM-CSF) as immunotherapy. Oncologist. 2007;12(suppl 2):22-26.
35. Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000;95:2269-2274.
36. Rutella S, Pierelli L, Bonanno G, et al. Role for granulocyte colony-stimulating factor in the generation of human T regulatory type 1 cells. Blood. 2002;100:2562-2571.
37. Fattorossi A, Battaglia A, Pierelli L, et al. Effects of granulocyte-colony-stimulating factor and granulocyte/macrophage-colony- stimulating factor administration on T cell proliferation and phagocyte cell-surface molecules during hematopoietic reconstitution after autologous peripheral blood progenitor cell transplantation. Cancer Immunol Immunother. 2001;49:641-648.
38. Weber J, Sondak VK, Scotland R, et al. Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 2003;97: 186-200.
39. Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18:226-232.